Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
NCT00677872 · Epix Pharmaceuticals, Inc. · PHASE2 · terminated · last registry update 2009-07-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Epix Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR2B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision